1009P - Network meta-analysis of first-line systemic therapies for advanced hepatocellular carcinoma: A comparison of objective response rates

Background

Advanced hepatocellular carcinoma (HCC) is a highly lethal disease with limited treatment options. The use of first-line (1L) systemic therapies showcase improved overall survival and quality of life. This study aimed to compare the objective response rate (ORR) of various systemic therapies for advanced HCC in 1L setting using a network meta-analysis.

Methods

A systematic literature review (SLR) and network meta-analysis (NMA) of randomized controlled trials (RCTs) was conducted to assess the efficacy of 1L systemic therapies for advanced HCC. Multiple databases, including PubMed, Embase, and the Cochrane Library were searched for relevant studies. The primary outcome of interest was the ORR of each therapy compared to placebo. The results were obtained for both fixed and random-effect models to estimate each therapy's relative risk (RR) and 95% credible intervals (CrI).

Results

A total of 12 RCTs met the inclusion criteria. The combination therapy of sintilimab + IBI305 had the highest ORR, with an RR of 13.6 (95% CrI: 3.69, 55.67) using fixed-effect and RR of 14.13 (95% CrI: 0.82, 120.1) using random-effect models. SUCRA values ranged from 0.075 for placebo to 0.761 for sintilimab + IBI30. SUCRA rankings were generally better for combination therapies followed by mono-therapies and placebo.

Conclusions

The NMA revealed that the combination therapies had the highest ORR among the systemic therapies in the 1L setting. The SUCRA values confirmed the high probability of these treatments ranking higher in terms of ORR and can be used to support treatment decision-making in clinical practice.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

G. Kaur, B. Singh, S. Attri, A. Sharma, P. Rai, S. Pandey: Financial Interests, Personal, Full or part-time Employment: Pharmacoevidence.